Real-world use patterns of angiotensin receptor-neprilysin inhibitor (sacubitril/valsartan) among patients with heart failure within a large integrated health system

Sacubitril/valsartan is a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI) that is now preferred in guidelines over angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) for patients with heart failure with reduced ejection fraction (HFrEF). However,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of managed care & specialty pharmacy 2022-10, Vol.28 (10), p.1173-1179
Hauptverfasser:	Kim, Brendan J, Huang, Cheng-Wei, Chung, Joanie, Neyer, Jonathan R, Liang, Brannen, Yu, Albert S, Kwong, Eric K, Park, Joon S, Hung, Peggy, Sim, John J
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aminobutyrates Angiotensin Receptor Antagonists - therapeutic use Angiotensin-Converting Enzyme Inhibitors Antihypertensive Agents - pharmacology Biphenyl Compounds Cross-Sectional Studies Delivery of Health Care, Integrated Heart Failure - drug therapy Humans Mineralocorticoid Receptor Antagonists - pharmacology Neprilysin - pharmacology Receptors, Angiotensin Stroke Volume Tetrazoles - pharmacology Tetrazoles - therapeutic use Valsartan - pharmacology Valsartan - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!